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Intestinal Stem Cells to Advance Drug Development, Precision, and
Regenerative Medicine: A Paradigm Shift in Translational Research
Abstract
Recent advances in our understanding of the intestinal stem cell niche and the role of key signaling pathways
on cell growth and maintenance have allowed the development of fully differentiated epithelial cells in 3D
organoids. Stem cell-derived organoids carry significant levels of proteins that are natively expressed in the gut
and have important roles in drug transport and metabolism. They are, therefore, particularly relevant to study
the gastrointestinal (GI) absorption of oral medications. In addition, organoids have the potential to serve as a
robust preclinical model for demonstrating the effectiveness of new drugs more rapidly, with more certainty,
and at lower costs compared with live animal studies. Importantly, because they are derived from individuals
with different genotypes, environmental risk factors and drug sensitivity profiles, organoids are a highly
relevant screening system for personalized therapy in both human and veterinary medicine. Lastly, and in the
context of patient-specific congenital diseases, orthotopic transplantation of engineered organoids could
repair and/or replace damaged epithelial tissues reported in various GI diseases, such as inflammatory bowel
disease, cystic fibrosis, and tuft enteropathy. Ongoing translational research on organoids derived from dogs
with naturally occurring digestive disorders has the potential to improve the predictability of preclinical
models used for optimizing the therapeutic management of severe chronic enteropathies in human patients.
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Abstract Recent advances in our understanding of the intestinal stem cell niche and the role
of key signaling pathways on cell growth and maintenance have allowed the development of
fully differentiated epithelial cells in 3D organoids. Stem cell-derived organoids carry
signiﬁcant levels of proteins that are natively expressed in the gut and have important roles in
drug transport and metabolism. They are, therefore, particularly relevant to study the
gastrointestinal (GI) absorption of oral medications. In addition, organoids have the potential
to serve as a robust preclinical model for demonstrating the effectiveness of new drugs more
rapidly, with more certainty, and at lower costs compared with live animal studies.
Importantly, because they are derived from individuals with different genotypes, environ-
mental risk factors and drug sensitivity proﬁles, organoids are a highly relevant screening
system for personalized therapy in both human and veterinary medicine. Lastly, and in the
context of patient-speciﬁc congenital diseases, orthotopic transplantation of engineered
organoids could repair and/or replace damaged epithelial tissues reported in various GI
diseases, such as inﬂammatory bowel disease, cystic ﬁbrosis, and tuft enteropathy. Ongoing
translational research on organoids derived from dogs with naturally occurring digestive
disorders has the potential to improve the predictability of preclinical models used for
optimizing the therapeutic management of severe chronic enteropathies in human patients.
KEY WORDS: dog; enteropathies; organoid; precision medicine; transplantation.
INTRODUCTION
Recent advances in biomedical research have allowed the
development of intestinal stem cells in three-dimensional (3D)
culture systems supporting ex vivo epithelial growth into
organoids [1, 2]. Stem cell-derived organoids have multiple
advantages over traditional 2D epithelial systems utilizing
cancer-derived cell lines (e.g., Caco-2, T84, and HT29) [3], or
spontaneously immortalized epithelial cells (e.g., rat intestinal
epithelial (RIE) cultures) which rarely reproduce the structure
and function of the intestinal epithelium. The beneﬁt of the 3D
organoid culture lies in the method’s ability to better harness
innate endogeneous cellular programming within higher order
cellular tissue organization [4]. The development of an ex vivo
gutmicrophysiological system thatmorphologically, biologically,
and chemically replicates the endogenous epithelium shows
tremendous potential to study the biology of epithelial diseases
[5, 6], and to evaluate the efﬁcacy and toxicity of orally
administered therapeutic drugs (Fig. 1). Furthermore, organoids
may be collected from hosts having different genotypes,
environmental risk factors (e.g., diet, microbiota), or drug
sensitivity proﬁles, thereby more faithfully reﬂecting the diver-
sity of the host background when cultured ex vivo. Yet, more
data are needed to link the information derived from the use of
organoids to the pathogenesis of the diseases of interest before it
can be used as a primary tool to optimize individualized
therapeutic options within a clinical setting.
The present Commentary provides a review of the
current knowledge on the biology of intestinal organoids,
their potential value in drug discover, precision medicine and
regenerative (i.e., transplantation medicine), and the
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remaining gaps that need to be resolved before it can be used
in a patient-speciﬁc manner.
DEFINITIONS, BACKGROUND, AND RATIONALE
Organoids: What they Are and why they Are Relevant to
Study the Biology of Intestinal Diseases?
Organoids can be propagated from embryonic, induced
pluripotent, or leucine-rich repeat containing G protein-
coupled receptor 5 (Lgr5)-positive stem cells, also known as
crypt base columnar (CBC) cells, located in the intestinal
crypt. Primary cultures developed from CBC cells or isolated
intestinal crypts are termed Benteroids^ or Bcolonoids,^
depending on the anatomic region (i.e., small vs. large
intestine) they are derived from [7]. Additionally, 3D cancer
cell cultures can be obtained from individual biopsies of
patients and are referred to as Btumor organoids.^ For
simpliﬁcation purposes, the generic term Borganoid^ will be
used consistently throughout the rest of the Commentary.
A rich body of literature has shown that 3D cell cultures are
superior to traditional 2D monolayer systems in mimicking
complex in vivo cellular heterogeneity [8–10]. The development
of 3D organoidmodels comprised of multiple cell types provides
an attractive approach to investigate key intra- and intercellular
signaling pathways that contribute to the development of
chronic enteropathies. Speciﬁcally, intestinal organoids can
facilitate detailed mechanistic studies on the molecular and
cellular reprogramming events that occur during inﬂammatory
bowel disease (IBD) and colorectal cancer (CRC) pathogenesis.
As described by Thoma et al. [11], multiple levels of complexity
can be built upon in 3D culture systems, ranging from simpler
models of cancer cell monocultures in liquid-based environ-
ments to more advanced models that include co-cultures with
endothelial, bacterial [12], and immune cells. These more
complex systems can also be used to study the effect of
environmental chemicals (such as endocrine disruptors) on
disease development [13]. The use of organoids as an enteric
infection model for bacteria and viruses crystallizes another
recent application of 3D models for understanding disease
pathophysiology. This was illustrated in a study by Rouch et al.
[14] where the authors developed a human organoid model to
elucidate the role of intestinal microfold (M) cells on the
proliferation of Salmonella typhimurium.
a
b
c
Fig. 1. Organoids: a promising in vitro system for drug discovery, precision, and regenerative medicine in human and veterinary medicine. (A)
Organoids can be used as a preclinical model to evaluate the efﬁcacy and safety of candidate drugs prior to live studies in animals and humans.
(B) In addition, because they are derived from individuals with different genotypes, organoids are a relevant screening system for precision
medicine. (C) Finally, transplantation of genetically engineered organoids has the potential to repair and/or replace damaged epithelial tissues
associated with several gastrointestinal diseases
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Comparison to Caco-2 Cells for the Study of Oral Drug
Transport and Metabolism
The Caco-2 cell model derived from human colon
adenocarcinoma primarily measures passive transcellular
and paracellular permeability of test compounds. Compared
to in vivo physiology, solute carrier transporters (e.g., organic
anion and cation (OAT/OCT) transporters) in the Caco-2
system are known to be expressed in relatively low amounts,
such that the permeability of oral drugs is typically
underestimated in this model [15]. This has been demon-
strated for ß-lactam antibiotics (e.g., cephalexin and amoxi-
cillin), which are completely absorbed in vivo despite being
poorly permeable across the Caco-2 cell monolayer [16, 17].
Overall, while the Caco-2 model can be considered relevant
for predicting the oral availability of highly permeable drugs,
it usually performs poorly in accurately predicting the
gastrointestinal (GI) absorption of low permeability com-
pounds [15]. In addition, while human-derived Caco-2 cells
are a commonly used in vitro system to study P-glycoprotein
(P-gp)-mediated drug efﬂux, there are several limitations to
this model, including the presence of tighter cellular junctions
than observed in normal enterocytes. Using 3D organoids,
Zhao et al. [8] were able to study P-gp-mediated efﬂux in the
presence of Rhodamine 123 which they later established as a
predictive model for P-gp inhibitor drug screening in humans.
Finally, although Caco-2 cell-based models are known to
express hydrolase, esterase, and brush-border enzymes, they
typically fail to express appreciable amounts of CYP3A4, one
of the main cytochromes contributing to the pre-systemic loss
of many orally administered drugs [13]. Negoro et al. [9] have
successfully established an organoid model that proved to be
relevant in the evaluation of drug-mediated CYP3A4 induc-
tion on victim drug oral bioavailability and could be used as
an alternative to the Caco-2 system.
Organoids and Organs-on-a-Chip
Organs-on-a-chip (OAC) are a recently emerged
microphysiological system that leverages computer microchip
manufacturing technology to create a microﬂuidic cell culture
device [18]. OAC aims to emulate organ-speciﬁc physiological
functions or cellular responses in a deﬁned 3D
microarchitecture and dynamic biomechanical motions of
the target organ. Typically, microﬂuidic OAC contain multi-
ple juxtaposed microchannels compartmentalized by a ﬂexi-
ble or a rigid porous membrane to reform a tissue-tissue
interface. This organ-speciﬁc microenvironment allows inter-
cellular interactions, for instance of the human intestine,
between the epithelium, endothelium, mesenchymal cells,
immune components, and living gut bacteria [19]. More
importantly, physiologically relevant cultures in the OAC
enable to reprogram cell morphogenesis, differentiation, and
cellular responses to mimic the complex in vivo environment.
For example, when Caco-2 cells are cultured in the gut-on-a-
chip, cells spontaneously undergo villus morphogenesis with
crypt-villus characteristics, differentiate into four lineages of
human small intestinal cells (i.e., absorptive, goblet,
enteroendocrine, and Paneth cells), and display key physio-
logical functions such as enhanced barrier function, mucus
production, and CYP3A4-mediated drug metabolism [20]. It
is notable that conventional 2D static culture of Caco-2 cells
never reproduces these reprogrammed functions in vitro.
Such features can help deciphering the pathophysiology of
chronic human enteropathies such as IBD, CRC, ileus, or
celiac disease.
Despite the great promise of the OAC technology, the
transfer of cells from a macroscopic environment (e.g., dishes,
ﬂasks, and well-plates) to a microﬂuidic system requires a
signiﬁcant revision of cell culture protocols. Precisely, multi-
ple factors distinguish microﬂuidic from macroscopic cell
cultures, such as different culture surfaces, reduced media
volumes, and vastly different rates of, and methods for,
medium exchange [21]. Additional challenges include the
ability to reproduce the architectural complexity of biological
tissues and organs in vitro in a miniaturized system, as well as
methods to connect these individual structures for recapitu-
lating tissue/organ interactions. Because the development of
OAC is labor and time intensive, microﬂuidic chips are
currently mainly used as a research tool, while patient-
derived organoids can be cultured more directly for precision
medicine purposes. Ultimately, organoid-derived epithelial
cells reﬂecting patients’ speciﬁcity integrated into OAC will
lay the foundation for future applications in personalized
therapy.
A PROMISING PRECLINICAL MODEL FOR DRUG
DEVELOPMENT
Currently, 9 out of 10 experimental drugs progressing
from discovery toward development fail in clinical studies
[22]. Recent reports have put the ﬁnal price of bringing a drug
to the market at approximately $1 billion dollars, with an
estimated research time running into multiple years [10]. In
Waring et al.’s retrospective analysis of drug development [23]
including 605 candidates, nonclinical (i.e., preclinical) toxicol-
ogy was the highest cause of drug attrition, accounting for
40% of failures in Research and Development (R&D)
programs. Out of the few candidates that were moved
forward to the Development stage, 35% attrition in phase II
studies was caused by failure to demonstrate clinical efﬁcacy.
These high failure rates highlight the urgent need for
alternative screening systems at the early stage of the R&D
lifecycle. Stem cell-derived mini-guts constitute an excellent
model to identify new molecular pathways that could lead to
novel therapeutic approaches. The potential of 3D organoids
to better reﬂect the biology of the in vivo intestinal
epithelium makes it a physiologically relevant platform for
high-throughput screening of drug candidates.
Yet, the success of therapeutic approaches based on stem
cells requires an improvement of disease models to more
faithfully recapitulate human phenotypes, including the use of
animals that have organs comparable in size and physiology
to those of humans [24, 25]. While rodents represent an
important model for dissecting mechanisms of many human
diseases, there is growing concern about the limitations of
these animal models with regards to recapitulation of disease
pathogenesis in humans. This was recently exempliﬁed by the
failures of the anti-IL17/IL13/IL10 candidate drugs in IBD
clinical trials. In fact, the need for large animal models to
improve translational science has been widely emphasized by
the National Institute of Health [26, 27]. As of today, porcine
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organoids are by far the most popular large animal model
used for biomedical GI research [28–31]. There are however
several important limitations of the porcine model. These
include: (i) the use of induced/artiﬁcial models of inﬂamma-
tion to reproduce part of the pathophysiology of the disease;
(ii) the absence of non-invasive medical techniques, such as
endoscopy, for long-term follow-up studies; and (iii) the cost
associated with these studies, since pigs are typically culled
after each experiment.
Of the large animal species used in translational GI
research, the dog is especially relevant because canine gut
physiology, diet, and intestinal microbiota are considered to
be highly comparable to that of humans [32–39]. Interestingly,
studies focusing on the relationship between the composition
of the gut microbiota and the development of intestinal
diseases have shown striking similarities between dogs and
humans, but diverging results between mice and humans [28,
40]. Importantly and similar to humans, dogs spontaneously
develop severe intestinal diseases such as IBD and CRC [36,
41–44] (Table I). Therefore, dogs can fulﬁll a pivotal role as a
clinically relevant animal model in the translation from mouse
to man. In contrast to pigs and mice, the natural occurrence
of chronic enteropathies in dogs allows in vivo clinical trials to
be conducted, in which the efﬁcacy and safety of drug
intervention can be monitored longitudinally, similar to
clinical studies in humans. Long-term, the complementary
information generated in ex vivo organoids and through
canine in vivo clinical studies can be used to select the most
efﬁcacious and safe therapeutics for clinical testing in human
patients.
CLINICAL APPLICATIONS: PRECISION AND
REGENERATIVE MEDICINE
For Personalized Oncology
Undoubtedly the greatest promise of the organoid
model lies in its potential application to precision medicine.
The ability to grow organoids from patients with intestinal
cancer enables personalized testing of a wide range of
therapeutics (and combination therapies) within weeks.
CRC is one of the most prevalent and debilitating disorders
of the GI tract, causing more than half a million deaths
annually worldwide [45]. The disease develops through at
least three major pathways, including (i) chromosomal
instability, (ii) mismatch repair, or (iii) CpG island methyl-
ator phenotype (CIMP) [46, 47]. The absolute number and
combination of genetic alterations in CRC confounds our
ability to determine the contribution of each of these
potential oncogenes on tumor development. The organoid
model is perfectly suited to study the effect of genetic and
epigenetic alterations on cellular differentiation and prolif-
eration. Speciﬁcally, Calvin Kuo et al. from the University of
Stanford have shown the utility of the highly tractable
organoid system for modeling the biology of CRC [48].
There is tremendous potential for using organoids to
develop more personalized medicine approaches, i.e., being
able to treat each individual patient with drugs that are
more likely to be efﬁcacious and safe [49, 50]. Using
surgically resected tumors from 20 previously untreated
CRC patients, van de Wetering et al. [51] developed an
automatized drug sensitivity platform in 3D organoid
culture and correlated chemotherapeutic drug sensitivity
with genomic proﬁles to identify molecular signatures
associated with drug responses. From their analyses, a
single colonoid culture was particularly sensitive to Wnt
secretion (porcupine) inhibitors while carrying a gene
mutation in the negative Wnt feedback regulator RNF43.
These authors further conﬁrmed the activity of cetuximab in
a subset of KRAS wild-type organoids reﬂecting observa-
tions made in the clinic [52] and demonstrated Nutlin-3a
effectiveness in TP53 wild-type organoids. Similarly,
organoids from primary human pancreatic ductal adenocar-
cinoma have been expanded for drug screening in human
patients showing poor response to chemotherapy protocols
[53].
Va r i ou s imag i n g t e chn i que s s u ch a s 1 8 F -
ﬂuorodeoxyglucose (FDG)-PET have been previously
explored as a predictor of stem cell response, but they
usually lack the resolution and sensitivity to accurately
quantify therapeutic response on a cellular level [54]. Walsh
et al. [55] showed that optical metabolic imaging (OMI) of
organoids derived from primary tumors can predict thera-
peutic response of anticancer drug responses in vivo. Their
results indicate that OMI is sensitive to therapeutic inter-
vention as early as 24 h after treatment of organoid with
candidate drugs while resolving cell sub-populations with
distinct metabolic phenotypes. Although most of the
laboratory protocols for primary tumor organoids require
the use of fresh tissues (which limits their clinical use), the
same authors recently showed that viable organoids could
be grown from bulk tissues slowly frozen in DMSO-
supplemented media [56]. They further demonstrated that
the drug response of organoids from frozen samples
correlated well with that of organoids obtained from fresh
biopsies such that organoids can be collected, frozen, and
used subsequently for drug testing purposes.
To Treat Patient-Specific Congenital Defects
Diseases that are associated with whole organ intestinal
failure manifest with severely reduced function of the
intestinal epithelial layer. As such, a growing number of
congenital diseases of the gut results in generalized loss of
nutrient absorption capacity in newborns. In addition,
extensive bowel resection in IBD or necrotizing enteroco-
litis can develop into functional short bowel syndrome.
These conditions often result in severe malnutrition and a
dependence on intravenous parenteral nutrition. Using a
dextran sulfate sodium (DSS)-induced model of IBD, Yui
et al. [57] demonstrated the feasibility of colonic organoid
transplantation in mice. Transplanted cells adhered to and
covered superﬁcially damaged tissues in only a few weeks.
One month after transplantation of colonic organoids,
donor-derived cells were able to form self-renewing intes-
tinal crypts that appeared to be functionally and histolog-
ically normal. Similar observations were made in a
subsequent study by Fordham et al. [58] following trans-
plantation of immature intestinal progenitor cells in DSS-
treated mice.
Additionally, orthotopic transplantation of engineered
organoids has the potential to repair or replace damaged
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epithelial tissues associated with chronic GI disorders,
such as IBD, tuft cell enteropathy, cobalamin deﬁciency,
and cystic ﬁbrosis (CF). The proof-of-principle use of
genome editing in organoids was demonstrated in a study
by Schwank et al. [59] in two CF patients. In this study,
CRISPR/Cas9 techniques were used to correct the anom-
alous CF transmembrane conductance regulator locus by
homologous recombination in cultured intestinal stem
cells. Following genome editing, the corrected allele was
expressed and demonstrated to be fully functional in
clonally expanded organoids. A similar approach was used
in COMMD1-deﬁcient dogs where gene supplemented
hepatic organoids facilitated restoration of liver function
as an effective strategy to treat copper storage disease.
COMMD1 deﬁciency is an autosomal recessive genetic
disorder which predisposes dogs to accumulate copper in
hepatic cells. As a result, these dogs develop copper-
induced hepatitis which is clinically very similar to
Wilson’s disease in humans [60, 61]. Functional assays to
determine intracellular copper accumulation have been
performed using a ﬂuorescence-based copper sensor [62–
65]. This assay showed that COMMD1−/− hepatic
organoids had a higher intracellular accumulation of
copper compared to normal organoids. Yet, after ex vivo
gene correction in hepatic organoids from dogs with
COMMD1 deﬁciency using lentivirus transfection, the
normal phenotype was restored and hepatic organoids
could be transplanted into canine patients. This study
therefore serves as a proof-of-concept that gene therapy
in hepatic organoids of dogs carrying genetic mutations is
possible and can, in the future, be developed into
regenerative medicine applications. Another good example
where gene editing into canine organoids could be used as
a preclinical model for human congenital disorders is
vitamin B12 deﬁciency (known as Imerslund-Gräsbeck
syndrome), which also develops spontaneously in certain
dog breeds, such as Border Collies, Giant Schnauzers, and
Beagles [66].
For Precision and Translational Medicine in Dogs
Similar to humans, many GI disorders in dogs such as
IBD, CRC, and congenital absorption defects speciﬁcally
affect the epithelial layer of the intestine. The organoid
model provides a unique approach for understanding how
gene polymorphisms can inﬂuence the response to thera-
peutic drugs with potential applications to personalized
therapy in veterinary medicine.
In fact, given the many similarities in gene polymor-
phisms between dogs and humans with IBD, there is a
signiﬁcant opportunity for the use of organoids from
diseased dogs to identify new molecular targets and
therapeutic strategies for human patients. A copious
amount of literature has established that human and canine
IBD shares common clinical and molecular features [34–39,
67–76]. In agreement with studies in humans, research on
IBD in affected dogs has led to the hypothesis that genetic
factors and enteric bacteria can play a pivotal role in the
pathogenesis of these disorders, owing to the abnormal
intestinal response to commensal microﬂora. More specif-
ically, a recent study showed that several Toll-like recep-
tors (2, 4, and 9) are upregulated in intestinal biopsies of
dogs with IBD [64]. These results are consistent with
previous descriptions in humans suffering from IBD.
lgarashi et al. [72] and Kathrani et al. [36, 73–75] have
shown that, similar to humans, single nucleotide polymor-
phisms (SNPs) in NOD2 and TLR5 play an important role
in canine IBD. Even more recently, Peiravan et al.
(manuscript under review) have investigated the genetics
of IBD in German Shepherd dogs and identiﬁed SNPs in
several genes (e.g., IL4, IL13, and SLC22A5) that are
known to be associated with IBD in humans. Finally, the
modulation of intestinal lamina propria lymphocytes P-gp
expression seems to play a similar role in both human and
dog IBD. In IBD patients scarcely responsive to steroid
treatment, P-gp is highly expressed and, in dogs showing a
good response to treatment, this protein is in fact modestly
represented [66].
The clinical relevance of the canine organoid model to
dog and human precision medicine also applies to colon
cancer, for which multiple gene mutations commonly found
in humans (e.g., tumor suppressors APC and TP53) have
been shown to be present in similar frequencies in canine
CRC biopsies [42–44]. The development of an ex vivo
model of canine CRC, representing samples of clinical and
molecular diversity similar to that seen in people, would
therefore constitute an essential step to promote transla-
tional and comparative research on CRC.
Table I. Comparative Features of IBD and Colorectal Cancer in Different Mammalian Species
Feature Human Dog Rodent
Genetic basis Yes Yes Engineered
Etiology Multifactorial Multifactorial +/− Multifactorial
Intact immune system Yes Yes +/−
Gut microbiota role Yes Yes Yes
Blood in stool Yes Yes Yes
Diarrhea Yes Yes Yes
Deﬁnitive diagnosis GI mucosal biopsy GI mucosal biopsy GI mucosal biopsy
Longitudinal studies Yes—endoscopy + histology Yes—endoscopy + histology No
Cancer treatment Surgery + chemotherapy Surgery + chemotherapy N/A
IBD treatment Diet + drugs Diet + drugs Drugs
Disease heterogeneity Yes Yes Variable
Using organoids to advance translational research
FUTURE DIRECTIONS
Although very promising, various challenges must be
overcome before the organoid model can be routinely used in
clinical practice. In particular, intestinal organoids typically
lack several essential components of the native digestive
microenvironment, including cells of the adaptive and innate
immunity, as well as the enteric nervous system. In addition,
the organoid system does not recapitulate the gradient of
nutrients which is present along the crypt-villus axis, or mimic
biomechanical forces that stem cells encounter in vivo [10].
There is therefore an increasing demand to integrate the
organoid system into a microﬂuidic organ-on-a-chip device, as
described by Takebe et al. [77] in a paper titled BSynergistic
Engineering: Organoids meet Organs-on-a-Chip.^
Currently, most applications of organoids for precision
medicine are related to the screening of anticancer therapeu-
tics, with only few descriptions in other indications such as
infectious diseases. This is partly due to the difﬁculty of co-
culturing bacteria or viruses with epithelial cells in the
organoid system. Speciﬁcally, human noroviruses—one of
the most common causes of epidemic gastroenteritis over the
world—have resisted cultivation efforts until very recently,
when Mary Estes’s group showed that these viruses replicate
in human organoid systems [78, 79]. This model has since
then proven useful in testing anti-viral drugs by measuring
viral load in infected organoid monolayers.
There are additional limitations to the use of organoids
for regenerative medicine. Organoid cultures usually depend
on mouse sarcoma-derived Matrigel, which precludes trans-
plantation of organoids into humans [18]. Future consider-
ations should therefore include alternative growth media
compositions and culture protocols to maximize the yield of
intestinal stem cells used for regenerative purposes [80]. Yet-
to-be-performed experiments must include transplantation
studies in large animal models to assess long-term safety,
efﬁcacy, and tumorigenicity of organoids for treatment of
chronic GI diseases. Additional concerns include the method
of tissue collection, the optimal route of mucosal delivery
(presumably via endoscopy), and design of a suitable delivery
vehicle to protect and sustain cells during transit while
allowing for mucosal adhesion [81].
Demonstration of drug efﬁcacy and safety in animals
remains the best way to gain sufﬁcient experience to initiate
ethically designed human trials. Given the many limitations of
the mouse model, there is a critical need to develop well-
characterized organoid systems in more relevant animal
disease models.
Using published protocols for mouse, pig, and human
organoid culture [82–84], our laboratory is currently devel-
oping canine organoids in an effort to ﬁnd cures for humans
and dogs suffering from similar diseases like IBD and CRC.
Our preliminary data, which include live cell bright-ﬁeld
imaging, Trypan Blue viability staining, and hematoxylin and
eosin (H/E, Fig. 2) showed a budding organoid morphology
consisting of differentiated columnar epithelium, and spher-
oid formation in a high Wnt conditioned medium, similar to
that seen in human organoids. Further characterization of the
canine organoid system, including transmission electron
microscopy, immunohistochemistry, RNA in situ hybridiza-
tion, and gene expression analysis is underway. This will be an
important step toward the validation of canine organoids as a
relevant in vitro system for modeling human diseases.
CONCLUDING REMARKS
Organoids are a powerful mechanistic tool for identifying
molecular targets that are relevant to the pathogenesis of
chronic intestinal diseases. They can also be used as a
platform for the screening of drug candidates that target the
Fig. 2. As the canine organoids grow, spheroids develop into large complex structures with
a pseudolumen (L) and crypt-like (C) projections, similar to human organoids. Canine
small organoid, 5-um-thick, parafﬁn-embedded section stained with H/E at ×400
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epithelial components of diseases such as IBD and CRC.
However, until it has been conﬁrmed that organoids can
express patient-speciﬁc disease pathways, its main utility is to
support potential therapeutic options and drug discovery as
an early exploratory tool. The hope is that this Commentary
will stimulate support for the research needed to enable
organoids to serve as a tool guiding medical decisions within
the clinical setting.
In addition, the possibility to grow organoids represen-
tative of the main targets for GI drug-related toxicity (e.g.,
gut, liver) opens up new avenues for complementary animal-
based toxicology studies. Importantly, because organoids are
derived from individuals with different genotypes, environ-
mental risk factors, and drug sensitivity proﬁles, they are a
highly relevant model system for targeted and personalized
therapy. Combination of organoids with microﬂuidic chips for
the integration of patient-derived cells could lay the founda-
tion for the future of precision medicine. Ultimately,
orthotopic transplantation of organoids has the potential to
repair or replace damaged epithelial tissues associated with a
wide range of intestinal disorders, including IBD, CF, and tuft
cell enteropathy.
Yet, the success of therapeutic approaches based on
organoids requires a substantial improvement of the animal
disease models they are derived from. Speciﬁcally, there are
growing concerns about the ability of murine models to
faithfully recapitulate human phenotypes. This is consistent
with several NIH initiatives (e.g., PAR-16-094 and PAR-16-
322) aiming at improving existing animal models to support
stem cell research and the development of new therapeutic
discoveries for digestive diseases. The dog is a particularly
relevant species since it shares similar environmental, geno-
mic, anatomical, and intestinal physiologic features with
humans. Our preliminary data show that canine organoids
can be successfully grown from intestinal crypts, and main-
tained in culture long-term. This is a signiﬁcant step toward
the development of a completely new animal model system
for GI research, with the added beneﬁt that dogs, similar to
humans, develop naturally occurring enteropathies. By inte-
grating this complement of knowledge, organoids can one day
serve as a tool to inform clinicians regarding preferred
patient-speciﬁc therapeutic options both in veterinary and
human medicine.
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